Composable Transformations: Diagnostics Innovation with Cepheid

Composable as an Enabler of Future Innovation, Part 2 [Interview with Cepheid, Danaher Group]

Looking to drive innovation within your enterprise, but don’t know where to start?

Watch our recent interview with Cepheid, an American molecular diagnostics company. The discussion touches on Cepheid's digital and commerce strategy, focusing on the impact of composable technology, the use of artificial intelligence (AI) and highlighting broader technology trends in the life science industry.

Gain valuable insights and practical strategies for navigating the complexities of digital transformation in the life science sector with Amelita Ebuna, Director of Digital Platforms at Cepheid, and Yury Bialykh, CTO at EPAM.

This webcast includes answers and insights to important questions, like:

What is Cepheid’s digital and commerce strategy?
How are modern digital and commerce experiences being adopted in the life science sector?
What was the logic behind leaping between electronic data interchange and composable commerce?
What has the impact of composable implementation been?
What important prerequisites must organizations endure in their composable journey?
How do you prepare your organization to leverage the upsides of AI?
Do AI capabilities influence the way you look for outside partners and vendors?
What is a strategy to cut through the hype of AI to understand what is real and what is needed?
Does having a composable stack help retrieve better insights and operational information?